Cargando…
Treatment of experimental autoimmune uveoretinitis with peroxisome proliferator-activated receptor α agonist fenofibrate
PURPOSE: The peroxisome proliferator-activated receptor α (PPARα) agonist has been approved for treating hypercholesterolemia and lipid abnormalities. Researchers have recently discovered that an anti-inflammatory effect of PPAR agonist may have the potential to treat autoimmune disease. This study...
Autores principales: | Osada, Miho, Sakai, Tsutomu, Kuroyanagi, Kana, Kohno, Hideo, Tsuneoka, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Vision
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225135/ https://www.ncbi.nlm.nih.gov/pubmed/25489225 |
Ejemplares similares
-
Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009) -
The Microbiota Determines Susceptibility to Experimental Autoimmune Uveoretinitis
por: Heissigerova, Jarmila, et al.
Publicado: (2016) -
Osteopontin is a biomarker for early autoimmune uveoretinitis
por: Kim, Jeongtae, et al.
Publicado: (2021) -
Fenofibrate, a peroxisome proliferator-activated receptor α-agonist, blocks lipopolysaccharide-induced inflammatory pathways in mouse liver
por: Won, Tae Wan
Publicado: (2013) -
Treatment of experimental autoimmune uveoretinitis with different natural compounds
por: LI, MAN, et al.
Publicado: (2016)